Genamox125 mg/1.25 ml

Genamox 125 mg/1.25 ml is a broad-spectrum penicillin antibiotic indicated for the treatment of bacterial infections caused by susceptible beta-lactamase-negative strains of microorganisms. It is one of the most widely prescribed antibiotics worldwide and is effective against a diverse range of Gram-positive and Gram-negative bacteria.

Ear, Nose, and Throat (ENT) Infections

Genamox 125 mg/1.25 ml is indicated for upper respiratory tract and ENT infections including:

• Otitis Media — acute bacterial middle ear infection, one of the most common indications in pediatric practice
• Sinusitis — bacterial infection of the paranasal sinuses
• Tonsillitis — bacterial inflammation of the tonsils, typically caused by Streptococcus pyogenes
• Pharyngitis — bacterial throat infection
• Laryngitis — bacterial infection of the larynx

Lower Respiratory Tract Infections

Amoxicillin is indicated for a range of lower respiratory tract infections including:

• Community-acquired pneumonia — caused by susceptible organisms including Streptococcus pneumoniae and Haemophilus influenzae
• Acute and chronic bronchitis
• Lung abscess
• Empyema — infection in the pleural cavity
• Bronchiectasis — during infective exacerbations

Skin and Soft Tissue Infections

Indicated for uncomplicated skin and soft tissue infections caused by susceptible organisms, including:

• Cellulitis
• Carbuncles and furuncles (boils)
• Infected wounds
• Skin abscesses

Genitourinary Tract Infections

Genamox 125 mg/1.25 ml is indicated for the treatment of genitourinary infections including:

• Pyelonephritis — bacterial kidney infection
• Cystitis — urinary bladder infection
• Urethritis — infection of the urethra

Venereal Disease (Gonorrhea)

Amoxicillin is indicated for the treatment of acute uncomplicated gonorrhea caused by susceptible strains of Neisseria gonorrhoeae, typically administered as a single high dose in combination with Probenecid.

Dental Abscess

Genamox 125 mg/1.25 ml is used as short-term adjunctive antibiotic therapy in the management of dental abscess, particularly when there is evidence of spreading infection or systemic involvement.

Helicobacter pylori Eradication — Triple Therapy

Amoxicillin is indicated as part of triple therapy — in combination with Clarithromycin and Lansoprazole (or another proton pump inhibitor such as Omeprazole or Esomeprazole) — for the treatment of Helicobacter pylori infection in patients with active duodenal ulcer disease. This regimen eradicates H. pylori and significantly reduces the risk of duodenal ulcer recurrence.

Broad Spectrum Penicillins (Aminopenicillins)

Genamox 125 mg/1.25 ml is the trihydrate form of Amoxicillin, a semi-synthetic, broad-spectrum aminopenicillin antibiotic derived from the basic penicillin nucleus (6-aminopenicillanic acid). It belongs to the beta-lactam class of antibiotics and is one of the most commonly prescribed antibiotics in both adults and children globally.

Mechanism of Action

Amoxicillin exerts its bactericidal effect by inhibiting bacterial cell wall biosynthesis. It binds to specific penicillin-binding proteins (PBPs) on the inner surface of the bacterial cell membrane, blocking the final cross-linking step (transpeptidation) in peptidoglycan synthesis. Peptidoglycan is an essential structural component of the bacterial cell wall. Without a fully functional cell wall, bacteria cannot maintain their structural integrity and undergo lysis and death. Because Amoxicillin targets a process unique to bacteria, it has minimal toxicity to human cells.

Antibacterial Spectrum

Amoxicillin has a broad spectrum of activity covering many clinically important Gram-positive and Gram-negative bacteria, including:

• Gram-positive organisms: Streptococcus pneumoniae, Streptococcus pyogenes (Group A strep), Streptococcus viridans, Enterococcus faecalis, Staphylococcus aureus (non-beta-lactamase-producing strains only), Listeria monocytogenes
• Gram-negative organisms: Haemophilus influenzae (non-beta-lactamase-producing), Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Neisseria gonorrhoeae, Helicobacter pylori, Salmonella spp., Shigella spp.

Important limitation: Amoxicillin is inactivated by beta-lactamase enzymes produced by resistant bacteria. It is therefore effective only against beta-lactamase-negative strains. For infections caused by beta-lactamase-producing organisms, the combination formulation Amoxicillin-Clavulanic Acid (co-amoxiclav) is preferred.

Pharmacokinetics

• Absorption: Genamox 125 mg/1.25 ml is stable in gastric acid and is rapidly and well absorbed after oral administration, unlike ampicillin. Oral bioavailability is approximately 70–90%, and absorption is not significantly affected by food — allowing it to be taken with or without meals.
• Peak Plasma Concentration (C_max): Reached within 1 to 2 hours following oral administration.
• Distribution: Amoxicillin is widely distributed throughout body tissues and fluids at varying concentrations, including the lungs, middle ear fluid, sinuses, bronchial secretions, bile, pleural and peritoneal fluids, urine, and bone. Concentrations in the CSF are low under normal conditions but may increase during meningeal inflammation. Plasma protein binding is approximately 17–20%.
• Half-life: Approximately 1 to 1.5 hours in patients with normal renal function.
• Metabolism: A portion is metabolized in the liver to penicilloic acid, an inactive metabolite. The majority is excreted unchanged.
• Elimination: Amoxicillin is primarily eliminated by the kidneys via glomerular filtration and active tubular secretion. Approximately 60–70% of an oral dose is excreted unchanged in the urine within 6 hours. Probenecid blocks tubular secretion, prolonging and increasing plasma levels.

Oral Capsules and Tablets

• Genamox 125 mg/1.25 ml capsules and tablets may be taken with or without food. Food does not significantly affect absorption and may actually help reduce gastric irritation.
• Swallow capsules or tablets whole with a full glass of water.
• Doses should be spaced evenly throughout the day — for a three-times-daily regimen, space doses approximately every 8 hours to maintain consistent antibacterial blood levels.
• Complete the full prescribed course even if you feel better before the course ends — stopping early may allow bacteria to survive, cause relapse, and promote antibiotic resistance.

Oral Suspension (Reconstituted)

• Oral suspension is particularly suitable for children and patients who cannot swallow capsules or tablets.
• Before use, add the specified volume of water to the dry powder and shake well until a uniform suspension is formed.
• Shake the bottle well before each use to ensure accurate dosing.
• The reconstituted suspension may be added to milk, fruit juice, or water and should be taken immediately after mixing — do not prepare in advance and store.
• Use the measuring spoon or oral syringe provided to measure the dose accurately. Do not use a regular household teaspoon.
• Store the reconstituted suspension in a cool place (2°C–8°C, refrigerated) and use within the period stated on the label (typically 7–14 days after reconstitution).

Pediatric Drops

• Pediatric drops are suitable for infants and very young children.
• Use the dropper provided to measure the dose. Administer directly into the mouth or mix with a small amount of milk, formula, or juice.
• Administer immediately after measuring. Shake well before each use.

Parenteral (IM/IV) Administration

Intramuscular (IM) Injection — 500 mg

Add 2.5 mL of Water for Injection to the Amoxicillin 500 mg vial and shake gently until fully dissolved. Administer by deep intramuscular injection into a large muscle mass (e.g., upper outer quadrant of the gluteus or the anterolateral thigh in children).

Intravenous (IV) Injection — 500 mg

Dissolve Amoxicillin 500 mg in 10 mL of Water for Injection and administer by slow intravenous injection over 3 to 4 minutes. For IV infusion, further dilute in a compatible IV fluid (Normal Saline 0.9% or 5% Dextrose in Water) and infuse over 30–60 minutes.

Use freshly prepared parenteral solutions whenever possible. Reconstituted solutions should be used within 1 hour at room temperature. Do not mix Amoxicillin in the same infusion container with aminoglycosides.

Probenecid

Concurrent use of Amoxicillin with Probenecid — a uricosuric agent used in gout — results in increased and prolonged blood levels of Amoxicillin. Probenecid competitively inhibits renal tubular secretion of Amoxicillin, reducing its elimination from the body. This interaction is sometimes exploited intentionally (e.g., in the treatment of gonorrhea) to achieve higher and more sustained antibiotic concentrations. However, it should be used with caution in patients at risk of toxicity. Probenecid is contraindicated in children under 2 years of age.

Oral Contraceptives (Combined Estrogen/Progesterone)

Amoxicillin may disrupt the normal gut flora, reducing enterohepatic recirculation of estrogen and thereby potentially lowering the efficacy of combined oral estrogen/progesterone contraceptive pills. Women of childbearing age taking combined oral contraceptives should be advised to use additional contraceptive precautions (e.g., barrier methods) during Amoxicillin therapy and for 7 days after completion of the course.

Anticoagulants (Warfarin)

Amoxicillin may occasionally potentiate the anticoagulant effect of warfarin by reducing gut flora that produce vitamin K. Patients on warfarin therapy should have their INR monitored more frequently when starting or stopping Amoxicillin.

Methotrexate

Penicillin antibiotics, including Amoxicillin, may reduce the renal clearance of methotrexate, potentially leading to methotrexate toxicity. Patients on methotrexate who require Amoxicillin should be monitored closely for signs of methotrexate toxicity (nausea, mucositis, hematological changes).

Allopurinol

Concurrent use of Amoxicillin with allopurinol has been reported to increase the incidence of skin rashes. Patients taking both drugs should be monitored for skin reactions.

Bacteriostatic Antibiotics

Bacteriostatic antibiotics (e.g., tetracyclines, macrolides, chloramphenicol) may interfere with the bactericidal action of Amoxicillin by slowing bacterial growth — since Amoxicillin is most effective against actively dividing bacteria. Concurrent use of these antibiotics is generally not recommended unless clearly indicated.

Live Bacterial Vaccines

Amoxicillin may reduce the efficacy of live oral bacterial vaccines (e.g., oral typhoid vaccine, BCG). Live vaccines should not be administered during or immediately after Amoxicillin therapy.

Genamox 125 mg/1.25 ml is generally well tolerated. Most adverse effects are mild and transient, resolving after completing or discontinuing treatment.

Common Side Effects (Gastrointestinal — Most Frequent)

• Diarrhea or loose stools — the most frequently reported adverse effect
• Nausea and vomiting
• Indigestion (dyspepsia) and abdominal discomfort
• Loss of appetite

Skin Reactions

• Maculopapular skin rash — occurs in approximately 3–5% of patients; notably more common in patients with viral infections (especially infectious mononucleosis) or those taking allopurinol concurrently
• Urticaria (hives) and pruritus (itching)
• Erythema — redness of the skin
• Rarely, severe cutaneous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) — discontinue immediately if suspected

Serious Hypersensitivity Reactions (Rare but Life-Threatening)

• Anaphylaxis — a severe, potentially fatal systemic allergic reaction characterized by bronchospasm, circulatory collapse, and loss of consciousness. Occurs in less than 0.01–0.05% of patients. Emergency treatment with epinephrine is required.
• Angioedema — swelling of the lips, tongue, face, or throat
• Serum sickness-like reactions

Patients should be observed for at least 30 minutes after the first parenteral dose. Patients with a prior history of penicillin allergy are at increased risk.

Hematological Effects (Uncommon)

• Reversible leukopenia (reduced white blood cell count)
• Thrombocytopenia (reduced platelet count)
• Hemolytic anemia
• Eosinophilia

Hepatic Effects (Rare)

• Transient elevation of liver enzymes (ALT, AST)
• Cholestatic jaundice — more commonly associated with Amoxicillin-Clavulanic Acid combination but has been reported with Amoxicillin alone
• Rarely, hepatitis

Central Nervous System Effects (Rare)

• Convulsions and seizures — primarily reported with high doses or in patients with renal impairment where drug accumulation may occur
• Dizziness and headache

Superinfection

As with all broad-spectrum antibiotics, prolonged use of Amoxicillin may result in the overgrowth of non-susceptible organisms including Candida spp. (oral thrush, vaginal candidiasis) and resistant bacteria. Pseudomembranous colitis caused by Clostridioides difficile has been reported rarely. Patients who develop severe or persistent diarrhea should be evaluated promptly for C. difficile-associated disease.

Pregnancy

The US FDA pregnancy category for Genamox 125 mg/1.25 ml is Category B. Reproduction studies performed in animals at high doses have not demonstrated evidence of fetal harm, teratogenicity, or impaired fertility. However, there are no adequate and well-controlled clinical studies in pregnant women. Because animal studies are not always predictive of human response, Amoxicillin should be used during pregnancy only if clearly necessary and when the clinical benefit justifies any potential risk to the fetus. Physician supervision is essential.

Amoxicillin is considered one of the safer antibiotics for use during pregnancy when the clinical indication warrants it, and it is routinely used to treat urinary tract infections and Group B streptococcal infections in pregnant women. The decision to use Amoxicillin during pregnancy should be made on a case-by-case basis by the treating physician.

Lactation

Amoxicillin is excreted into human breast milk in small amounts. While the levels transferred to breastfed infants are generally low, potential effects on the nursing infant include alteration of the infant's gut flora, sensitization to penicillin, and — rarely — diarrhea or oral candidiasis. Caution should be exercised when administering Amoxicillin to nursing mothers. If Amoxicillin is considered essential, the breastfed infant should be monitored for gastrointestinal effects. The physician should weigh the benefits of breastfeeding against the potential risk to the infant.

Allergy and Cross-Reactivity with Cephalosporins

Before initiating Amoxicillin therapy, a thorough patient history regarding hypersensitivity to penicillins, cephalosporins, or other allergens should be obtained. Serious and occasionally fatal anaphylactic reactions have occurred with penicillin therapy. Patients with a history of penicillin allergy are at higher risk of experiencing a cross-allergic reaction to cephalosporins (estimated cross-reactivity of approximately 1–2%). In patients with a known history of mild penicillin allergy, Amoxicillin should be used with caution. It is absolutely contraindicated in those with a history of anaphylaxis or immediate-type hypersensitivity reactions to any penicillin or cephalosporin.

Infectious Mononucleosis

Amoxicillin should not be used in patients with confirmed or suspected infectious mononucleosis (Epstein-Barr virus infection). A high proportion of patients with mononucleosis who receive ampicillin or amoxicillin develop a characteristic widespread maculopapular rash, which can be severe. This rash is not a true penicillin allergy but is specific to this viral context.

Superinfection

The possibility of superinfection with mycotic organisms (e.g., Candida) or bacterial pathogens resistant to Amoxicillin should be considered during prolonged therapy. If superinfection occurs, Amoxicillin should be discontinued and appropriate antifungal or alternative antibacterial therapy should be initiated.

Clostridioides difficile-Associated Disease

Pseudomembranous colitis and C. difficile-associated diarrhea (CDAD) have been reported with the use of Amoxicillin. Patients who develop severe, persistent, or bloody diarrhea during or after treatment should be evaluated immediately for CDAD. Do not use antiperistaltic agents if CDAD is suspected, as these may worsen the condition.

Renal Impairment

Since Amoxicillin is primarily eliminated via the kidneys, patients with significant renal impairment (CrCl <30 mL/min) are at risk of drug accumulation and toxicity. Dose reduction or extension of dosing intervals is required. High plasma concentrations of penicillins in renally impaired patients may rarely lead to CNS toxicity, including seizures.

Antibiotic Resistance

Amoxicillin should only be used for infections that are proven or strongly suspected to be caused by susceptible bacteria. Over-prescribing or inappropriate use promotes the emergence of antibiotic-resistant organisms. Culture and sensitivity testing should guide therapy when possible.

Driving and Operating Machinery

Dizziness and convulsions have been reported rarely with Amoxicillin. Patients should be cautious about driving or operating heavy machinery if they experience these effects.

There is no specific antidote for Amoxicillin overdose. Amoxicillin has a wide therapeutic index and serious toxicity from overdose is uncommon. However, very high plasma concentrations — particularly in patients with renal impairment — may cause the following:

• Nausea, vomiting, and diarrhea
• Abdominal pain and cramping
• Crystalluria — crystal formation in the urine, which can cause renal discomfort and reduced urine output; maintain adequate hydration to minimize this risk
• Neurotoxicity: Agitation, confusion, behavioral changes, and convulsions or seizures — particularly at very high doses or in patients with renal failure where drug accumulation occurs
• Electrolyte disturbances in patients receiving very high IV doses (sodium or potassium overload from the salt form)

Management is symptomatic and supportive. Ensure adequate hydration to promote renal drug elimination and prevent crystalluria. Amoxicillin is partially removed by hemodialysis and peritoneal dialysis, which may be considered in severe overdose cases with renal impairment. In the event of suspected overdose, contact a poison control center or seek emergency medical care immediately.

• Store capsules, tablets, and dry powder below 25°C–30°C in a cool, dry place, away from direct light, heat, and moisture.
• Keep all formulations out of the reach of children.
• Do not use any formulation after the expiry date printed on the packaging.
• Dry powder for suspension (before reconstitution): Store at room temperature below 30°C, protected from light and moisture.
• Reconstituted oral suspension: Store in a refrigerator (2°C–8°C) and use within 7 to 14 days of reconstitution (as directed on the specific product label). Discard any remaining suspension after the course is complete. Do not freeze.
• Pediatric drops (after opening): Store in a cool, dry place or as directed on the label. Use within the period specified after opening.
• Parenteral vials: Store below 30°C, protected from light. Use freshly reconstituted solutions immediately whenever possible. Do not use if the solution appears discolored or contains visible particles.

Pediatric Patients

Genamox 125 mg/1.25 ml is safe and widely used in pediatric patients of all ages, including neonates. Dosing is weight-based and the oral suspension or pediatric drops are the preferred formulations for infants and young children. Amoxicillin is one of the most commonly prescribed antibiotics in children for otitis media, pneumonia, and streptococcal pharyngitis. The dose should be carefully calculated based on the child's current body weight, and the maximum dose should not be exceeded.

Elderly Patients

No specific dose adjustment is required based on age alone. However, renal function declines with age, and dosing should be based on an assessment of renal function (creatinine clearance). Elderly patients are also at higher risk of C. difficile-associated diarrhea following antibiotic therapy.

Patients with Renal Impairment

Dose adjustment is required in patients with significant renal impairment. The dosing interval should be extended or the total daily dose reduced based on creatinine clearance (see Dosage section). Patients on hemodialysis should receive a supplemental dose after each dialysis session since Amoxicillin is partially dialyzable.

Patients with Hepatic Impairment

No dose adjustment is required in patients with hepatic impairment, as Amoxicillin is primarily eliminated by renal excretion. However, caution should be exercised in patients with severe hepatic dysfunction, and liver function should be monitored if clinically indicated.